---
title: CROs offering Biomarker Assays with Oligonucleotide
path: /explore/biomarker-assays/oligonucleotide
companies_count: 11
---

# CROs offering Biomarker Assays with Oligonucleotide

11 published CROs match Biomarker Assays and Oligonucleotide.

Locations in this set include United States, China, India, United Kingdom, 30 countries, and 30+ countries.

Capabilities that show up most often in this set: Bioanalysis, Translational Research, Discovery Research, LC-MS Bioanalysis (Small Molecule), and Ligand-Binding Bioanalysis (Large Molecule).

## Matching companies

- [Aliri Bioanalysis](/companies/aliribio)
  - Bioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise.
- [Amador Bioscience](/companies/amadorbioscience)
  - Amador Bioscience provides bioanalysis and biomarker services, including LCMS, immunoassays, flow cytometry, and immunogenicity testing, alongside clinical pharmacology modeling and regulatory affairs support. Its labs are GLP compliant, and its teams work across the US, China, and Europe.
- [Aragen Life Sciences](/companies/aragen)
  - Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
- [Axcelead Drug Discovery Partners, Inc.](/companies/axcelead)
  - Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.
- [Certara](/companies/certara)
  - Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
- [ChemPartner](/companies/chempartner)
  - Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
- [Pharmaron](/companies/pharmaron)
  - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- [SoCal Biosciences, Inc.](/companies/socalbiosci)
  - San Diego-based bioanalytical CRO specializing in assay development and analysis for mRNA, oligonucleotides, and large molecules across discovery through clinical development phases.
- [Syngene International](/companies/syngeneintl)
  - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- [TATAA Biocenter](/companies/tataa-biocenter)
  - GLP- and GCLP-compliant molecular CRO specializing in bioanalysis for gene therapy, RNA therapeutics, and advanced modalities, offering qPCR, NGS, and plasma proteomics services since 2001.
- [WuXi AppTec](/companies/wuxiapptec)
  - Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.